Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
MRNA - Moderna, Inc.
Market Cap 42.02B P/E 9.48 EPS this Y 22.20% Ern Qtrly Grth -
Income -5.87B Forward P/E -27.08 EPS next Y 16.10% 50D Avg Chg -11.00%
Sales 5.05B PEG 0.13 EPS past 5Y - 200D Avg Chg -27.00%
Dividend N/A Price/Book 2.24 EPS next 5Y -51.34% 52W High Chg -49.00%
Recommedations 2.70 Quick Ratio 3.77 Shares Outstanding 384.40M 52W Low Chg -
Insider Own 9.52% ROA -15.42% Shares Float 347.11M Beta 1.67
Inst Own 72.69% ROE -40.94% Shares Shorted/Prior 27.61M/25M Price 110.22
Gross Margin -62.99% Profit Margin -116.18% Avg. Volume 3,254,514 Target Price 101.94
Oper. Margin -565.56% Earnings Date Oct 31 Volume 4,434,575 Change -3.26%
Healthcare | Biotechnology | United States
About Moderna, Inc.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc. News
12/16/24 Palantir Falls Despite Nasdaq 100 News, MicroStrategy Rises; Super Micro Gets The Axe
12/16/24 What's Going On With Moderna Stock On Monday?
12/16/24 Some of This Year's Big Losers Look Good to Me
12/16/24 Palantir, MicroStrategy, and Axon Are Joining the Nasdaq 100. Only 1 of the Stocks Is Rising.
12/16/24 MicroStrategy, Palantir, Axon to join the Nasdaq 100 next week
12/13/24 Annual Changes to the Nasdaq-100 Index®
12/13/24 Alphabet and 9 More Stocks to Buy for 2025
12/13/24 Is Moderna Stock A Sell In December 2024 With Deep Losses Projected For The Fourth Quarter?
12/13/24 The specter of RFK Jr. has investors fretting about a onetime vaccine wunderkind
12/12/24 Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies
12/11/24 FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
12/11/24 Moderna reinstated with an Underperform at BofA
12/10/24 BofA downgrades Moderna, says it's 'tough time' to be vaccine maker
12/10/24 S&P 500 Gains and Losses Today: Walgreens Pops Following Reports of Buyout Talks
12/10/24 Moderna Stock Is Struggling. BofA Doesn’t See Things Getting Better.
12/06/24 Here's Why We're Watching Moderna's (NASDAQ:MRNA) Cash Burn Situation
12/05/24 Is Now the Time to Buy 3 of the S&P 500's Worst-Performing Stocks of 2024?
12/05/24 Moderna opens Southern Hemisphere’s only mRNA manufacturing facility in Victoria
12/04/24 Hong Kong residents reticent to get latest Covid-19 jab, Moderna survey finds
12/03/24 Moderna shares could slump over 30% on negative CMV reading: Leerink
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Hoge Stephen President President Dec 27 Sell 100.01 45,000 4,500,450 1,531,063 12/28/23
Klinger Shannon Thyme Chief Legal Officer Chief Legal Officer Dec 07 Sell 79.09 563 44,528 7,912 12/11/23
AFEYAN NOUBAR Director Director Nov 01 Sell 75.73 10,000 757,300 2,146,931 11/03/23
AFEYAN NOUBAR Director Director Oct 25 Sell 77.49 10,000 774,900 2,156,931 10/27/23
AFEYAN NOUBAR Director Director Oct 11 Sell 104.26 15,000 1,563,900 2,166,931 10/13/23
Mock James M Chief Financial Offi.. Chief Financial Officer Oct 05 Sell 102.5 2,858 292,945 2,952 10/10/23
AFEYAN NOUBAR Director Director Oct 04 Sell 102.05 15,000 1,530,750 2,181,931 10/06/23
AFEYAN NOUBAR Director Director Sep 27 Sell 99.37 10,000 993,700 2,196,931 09/29/23
AFEYAN NOUBAR Director Director Sep 20 Sell 104.9 15,000 1,573,500 2,206,931 09/22/23
AFEYAN NOUBAR Director Director Sep 13 Sell 111.17 15,000 1,667,550 2,221,931 09/15/23
AFEYAN NOUBAR Director Director Sep 06 Sell 108.08 15,000 1,621,200 1,982,209 09/08/23
Garay Arpa Chief Commercial Off.. Chief Commercial Officer Sep 05 Sell 108.4 574 62,222 3,113 09/07/23
AFEYAN NOUBAR Director Director Aug 30 Sell 115.96 15,000 1,739,400 1,997,209 09/01/23
AFEYAN NOUBAR Director Director Aug 23 Sell 114.78 15,000 1,721,700 2,012,209 08/25/23
AFEYAN NOUBAR Director Director Aug 16 Sell 97.71 10,000 977,100 2,027,209 08/18/23
Hoge Stephen President President Aug 17 Sell 100.00 15,000 1,500,000 1,587,579 08/18/23
AFEYAN NOUBAR Director Director Aug 02 Sell 112.08 15,000 1,681,200 2,037,209 08/04/23
AFEYAN NOUBAR Director Director Jul 26 Sell 120.47 15,000 1,807,050 2,052,209 07/28/23
AFEYAN NOUBAR Director Director Jul 19 Sell 125.16 15,000 1,877,400 2,067,209 07/21/23
AFEYAN NOUBAR Director Director Jul 12 Sell 125.9 15,000 1,888,500 2,082,209 07/14/23
AFEYAN NOUBAR Director Director Jul 05 Sell 125.84 15,000 1,887,600 2,097,209 07/07/23
AFEYAN NOUBAR Director Director Jun 28 Sell 121.33 15,000 1,819,950 2,112,209 06/30/23
AFEYAN NOUBAR Director Director Jun 21 Sell 122.45 15,000 1,836,750 2,127,209 06/23/23
AFEYAN NOUBAR Director Director Jun 14 Sell 126.73 15,000 1,900,950 2,142,209 06/16/23
AFEYAN NOUBAR Director Director Jun 07 Sell 126.17 15,000 1,892,550 2,157,209 06/09/23
Garay Arpa Chief Commercial Off.. Chief Commercial Officer Jun 05 Sell 125.75 2,290 287,968 2,547 06/07/23
AFEYAN NOUBAR Director Director May 31 Sell 127.7 15,000 1,915,500 2,172,209 06/02/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Apr 26 Sell 131.62 80,000 10,529,600 5,411,946 04/28/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Apr 26 Option 0.99 80,000 79,200 5,451,946 04/28/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Apr 19 Sell 142.81 80,000 11,424,800 5,411,946 04/21/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Apr 19 Option 0.99 80,000 79,200 5,451,946 04/21/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Apr 05 Sell 155.78 80,000 12,462,400 5,411,946 04/07/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Apr 05 Option 0.99 80,000 79,200 5,451,946 04/07/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Mar 22 Sell 150.21 80,000 12,016,800 5,411,946 03/24/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Mar 22 Option 0.99 80,000 79,200 5,451,946 03/24/23
AFEYAN NOUBAR Director Director Mar 01 Sell 139 10,000 1,390,000 2,187,209 03/03/23
Hoge Stephen President President Feb 28 Sell 138.03 1,072 147,968 1,629,031 03/02/23
Hoge Stephen President President Feb 28 Option 0 2,410 1,630,103 03/02/23
AFEYAN NOUBAR Director Director Feb 15 Sell 173.17 10,000 1,731,700 2,207,209 02/17/23
Hoge Stephen President President Feb 09 Sell 163.9 245 40,156 1,627,693 02/13/23
Hoge Stephen President President Feb 09 Option 0 522 1,627,938 02/13/23
AFEYAN NOUBAR Director Director Feb 08 Sell 166.92 20,000 3,338,400 2,217,209 02/10/23
AFEYAN NOUBAR Director Director Jan 25 Sell 194.33 10,000 1,943,300 2,237,209 01/27/23
AFEYAN NOUBAR Director Director Jan 18 Sell 200.20 10,000 2,002,000 2,247,209 01/20/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Jan 18 Sell 198.64 80,000 15,891,200 5,411,946 01/20/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Jan 18 Option 0.99 80,000 79,200 5,451,946 01/20/23
AFEYAN NOUBAR Director Director Jan 11 Sell 188.57 10,000 1,885,700 2,257,209 01/13/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Jan 11 Sell 184.24 80,000 14,739,200 5,411,946 01/13/23
Bancel Stephane Chief Executive Offi.. Chief Executive Officer Jan 11 Option 0.99 80,000 79,200 5,451,946 01/13/23
AFEYAN NOUBAR Director Director Jan 04 Sell 182.15 10,000 1,821,500 2,267,209 01/06/23